IDEXX Labs (IDXX) Tops Q3 EPS by 2c; Updates FY16 Outlook; Guides FY17 EPS Above Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
IDEXX Laboratories Announces Third Quarter Results
November 1, 2016 7:00 AM EDTWESTBROOK, Maine, Nov. 1, 2016 /PRNewswire/ --
Reports revenue growth of 10% on both a reported and organic basis, reflecting CAG Diagnostics recurring revenue growth of 12% and strong premium instrument placements Delivers EPS of $0.62, a 29% increase year over year as reported, or 22% on an Adjusted constant currency basis Achieves 18% growth in premium instrument placements, including 562 IDEXX SediVue Dx placements Adjusts 2016 revenue growth and EPS outlook toward the high end of previous guidance range, and provides preliminary 2017 financial guidance for organic revenue growth of 9% - 10.5% and earnings per share... More